Michael James McClellan is CFO & EVP at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). They have made 2 open-market trades across 1 company since 2018, most recently 2019-11-05.
CIK 0001721544
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TEVA | 16,140 | $669K |
Shares reported on the most recent Form 4, priced at the 2019-11-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TEVA | SELL · 10b5-1 | 2019-11-05 | 2019-11-06 | $8.83 | $2K | +20.7% | +15.8% | +40.7% |
| TEVA | SELL · 10b5-1 | 2019-09-18 | 2019-09-20 | $7.83 | $11K | -4.8% | +11.2% | +36.0% |
| TEVA | SELL · 10b5-1 | 2019-03-18 | 2019-03-19 | $16.63 | $4K | -6.9% | -14.8% | -51.3% |
| TEVA | SELL · 10b5-1 | 2019-03-04 | 2019-03-05 | $16.88 | $6K | +0.2% | -7.8% | -46.0% |
| TEVA | SELL | 2018-11-05 | 2018-11-07 | $22.73 | $8K | -6.3% | -17.3% | -15.0% |
| TEVA | SELL | 2018-03-19 | 2018-03-20 | $17.88 | $5K | -4.9% | +0.5% | +37.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.